Loading
Life sciences · Journal article
BMC Endocrine Disorders · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic syndrome (MetS) has been linked to thyroid nodules, but most evidence relies on any-size detection dominated by clinically trivial lesions and adjusts for few confounders. Using a body-mass-index (BMI)-based operational definition (a ‘MetS-like’ phenotype, distinct from formally defined MetS), we examined its association, and that of its components and overall metabolic burden, with size-threshold thyroid nodules (≥ 1.0 cm; primary outcome) and, as an exploratory outcome, sonographically suspicious nodules (TI-RADS ≥ 4). In this cross-sectional study following STROBE, the first thyroid ultrasound of each adult attending a Beijing health-management centre (2014–2026) was analysed, with metabolic laboratory data linked by examination date (± 60 days). After excluding participants without ultrasound or with incomplete metabolic data, 50,023 formed the complete-case sample; included and excluded participants were compared. A metabolic-burden score (0–5) counted BMI-defined obesity (≥ 28), elevated blood pressure, elevated glucose, high triglycerides and low HDL-cholesterol. Odds ratios (OR; logistic) and prevalence ratios (PR; robust-variance modified Poisson) were adjusted for age and sex; components were also entered simultaneously. Robustness was assessed by the waist-based Chinese Diabetes Society (CDS) definition, additional adjustment for uric acid, C-reactive protein and thyroid peroxidase antibody in available subsets, period-stratified analysis, multiple imputation, restricted cubic splines and E-values. Nodules ≥ 1.0 cm occurred in 3,854 participants (7.7%) and TI-RADS ≥ 4 nodules in 619 (1.2%). The MetS-like phenotype was associated with nodule ≥ 1.0 cm (OR 1.52 (1.42–1.63); PR 1.45 (1.36–1.54)). BMI-defined obesity, elevated blood pressure, elevated glucose and low HDL-cholesterol remained associated when entered simultaneously, whereas high triglycerides did not. Prevalence rose from 4.4% to 12.2% across 0–5 components (trend P < 0.001). Estimates were stable across the CDS definition (OR 1.61), additional confounder adjustment, examination period, and multiple imputation that included the outcome (OR 1.50); the E-value was 2.30. TI-RADS ≥ 4 nodules were analysed only from 2020 onward, when structured grading became available. No association was seen (MetS-like OR 0.97, 0.82–1.16), but the estimate was imprecise and a small-to-moderate association could not be excluded. A higher BMI-based metabolic burden showed a graded cross-sectional association with size-threshold, but not sonographically suspicious, thyroid nodules. These associations may inform metabolic-health counselling; given the cross-sectional design they do not establish causation and do not support changing thyroid-ultrasound follow-up intensity.